心脏标记物市场规模报告| 2031 年分享、趋势和增长动力

Publication Month : Feb 2024

  • Report Code : TIPRE00037802
  • Category : Medical Device
  • Status : Upcoming
  • No. of Pages : 150
Inquire Before Buy

PRICING

$5190

$4671

【研究报告】心脏标志物市场规模预计将从2022年的96.8亿美元增长到2030年的248.0亿美元;预计 2022 年至 2030 年复合年增长率将达到 12.5%。

市场洞察和分析师观点:

心脏标志物是当心肌受损或受到压力时释放到血液中的物质。这些标记物用于识别和监测各种心脏状况。这些标记物通过血液测试进行测量,其水平可以提供有关心脏功能的重要信息。心脏标志物对于急性冠脉综合征等多种病症的及时、准确诊断和治疗以及预后判断具有重要意义。随着全球人口老龄化和心血管疾病 (CVD) 发病率的不断上升,对可促进早期诊断和风险评估的高灵敏度和特异性心脏标志物检测的需求不断增加。此外,将人工智能 (AI) 和机器学习算法纳入心脏标志物分析中可以提高预测准确性和个性化治疗方法。心脏生物标志物领域的技术进步为心脏生物标志物行业带来了利润丰厚的机会。

增长动力:

< /span>

根据世界卫生组织 (WHO) 的数据,心血管疾病是全世界发病和死亡的主要原因。 CVD包括冠心病、心脏病发作、心肌缺血等。由于吸烟、糖尿病、肥胖和生活方式改变等多种因素,全世界心血管疾病的负担正在增加。与心血管疾病相关的其他危险因素包括高血压、胆固醇水平升高和糖尿病。心脏病发作和中风通常是由脂肪沉积物阻塞血管、扰乱流向心脏或大脑的血液引发的。各种心血管疾病的日益流行引发了对改进诊断方法的需求。

根据世界心脏联合会项目发布的报告,全世界有超过 5 亿人患有心血管疾病。 CVD,2021 年将导致 2050 万人死亡。根据世界卫生组织的数据,每年有 1790 万人死于 CVD,占全球死亡人数的 32%。根据美国心脏协会的数据,美国几乎一半的成年人患有某种心血管疾病。在美国,每 5 例死亡中就有 1 例是由 CVD 造成的。预计到 2035 年,将有超过 1.3 亿人(即美国人口的 45.1%)患有某种类型的 CVD。

根据世界卫生组织的数据,约有 3000 万人患有某种类型的 CVD。每年都会中风。根据美国疾病控制与预防中心 (CDC) 的数据,每 40 秒就有一名美国人心脏病发作。每年约有 805,000 名美国人心脏病发作,其中约 605,000 人是首次心脏病发作。根据 2021 年百万之心数据,美国每年约有 150 万例心脏病发作(心肌梗塞)和中风。根据 CDC 2022 年估计,2010 万美国成年人患有冠状动脉疾病。此外,欧洲心脏病学会报告称,患有房颤的患者发生中风的风险是其五倍,全国中风病例中的20-30%是由房颤引起的。

心血管疾病发病率的上升需要准确、及时的诊断。预监测和预诊断可以预防大多数类型的心血管疾病。生物标志物是在特定心血管状况下释放到血液中的某些内源性物质,表明心脏功能异常。因此,心脏标志物的使用有助于个体检测心血管异常。因此,心血管疾病数量的增加正在推动预测期内心脏标志物市场的增长。

战略见解

报告细分和范围:

全球心脏标记物市场根据标记物类型、适应症、最终用户和地理位置进行细分。根据标记物的类型,市场分为肌钙蛋白、b 型利钠肽、肌酸激酶 MB、肌红蛋白等。根据适应症,市场分为充血性心力衰竭、心肌梗塞、急性冠状动脉综合征等。就最终用户而言,心脏标记物市场分为医院、诊断实验室、即时检测设施等。心脏标记物市场根据地理位置分为北美(美国、加拿大和墨西哥)、欧洲(德国、法国、意大利、英国、西班牙和欧洲其他地区)、亚太地区(澳大利亚、中国、日本、印度、韩国和亚太地区其他地区)、中东和印度非洲(南非、沙特阿拉伯、阿联酋以及中东和非洲其他地区)以及南美和非洲中美洲(巴西、阿根廷以及南美洲和中美洲其他地区)。

细分分析:

心脏标记物市场按标记物类型分为肌钙蛋白、b 型利钠肽、肌酸激酶 MB、肌红蛋白等。到 2022 年,肌钙蛋白细分市场将占据重要市场份额。肌钙蛋白是心肌和骨骼肌收缩所需的蛋白质。心肌肌钙蛋白测试可测量血液中肌钙蛋白 T (TnT) 或肌钙蛋白 I (TnI) 的水平。仅当心肌受损时(例如心脏病发作期间),这些蛋白质才会出现在血液中。心肌肌钙蛋白测试可检测心肌的损伤情况。心肌受损越严重,血液中肌钙蛋白的水平就越高。心肌肌钙蛋白是迄今为止最常用的生物标志物,并且具有最高的已知敏感性。肌钙蛋白是诊断和治疗 CVD 的重大进步。当心肌细胞受到损伤时,这些高度特化的蛋白质就会被排放到血液中。肌钙蛋白生物标志物对于诊断心脏病、评估心脏事件的严重性、指导选择适当的治疗方案以及预测患者的预后至关重要。此外,通过检测血液中的微量肌钙蛋白,高灵敏度肌钙蛋白检测进一步提高了早期诊断心脏异常的能力,即使在没有临床症状的情况下也是如此。

心脏标记市场,按标记类型划分 – 2022年和2030年

根据适应症,心脏标志物市场分为心肌梗死、充血性心力衰竭、急性冠脉综合征、和别的。由于与高收入国家相比,低收入和中等收入国家的疾病负担日益增加,急性冠脉综合征细分市场在 2022 年将占据重要的市场份额。久坐工作的增加和快速城市化等因素正在推动疾病的发生。心肌肌钙蛋白 T 和 I 生物标志物检测已成为疾病诊断的主要诊断方法。 PrecisionCHD 是一种用于早期识别冠心病的综合表观遗传学血液测试,由 Cardio Diagnostics 于 2023 年 2 月推出。该测试利用机器学习模型来分析基因组和表观基因组数据以及遗传生物标志物和表观遗传学。它将患者的生物标志物概况与可改变的危险因素联系起来,这些危险因素是导致冠心病的重要因素,包括吸烟、糖尿病、高血压和高胆固醇。然而,心肌梗塞细分市场预计将在 2022 年至 2030 年实现最快的复合年增长率。

根据最终用户,心脏标记物市场分为医院、诊断实验室、即时检测设施等。到 2022 年,医院细分市场将占据重要的市场份额。由于患者人数较多且拥有先进的诊断设施,医院将占据最大份额。从急诊室到住院护理机构,心脏生物标志物对于诊断急性心血管事件、识别患者风险和为治疗决策提供信息至关重要。这些生物标志物的存在和准确的解释使医疗保健专业人员能够及时提供干预措施并改善患者的治疗效果。

区域分析:

根据地理位置,心脏标记物市场主要分为北美、欧洲、亚太地区、南美和亚太地区。中美洲、中东和非洲非洲。到 2022 年,北美将占据全球市场的重要份额。北美心脏标志物市场的增长归因于包括 CVD 在内的心脏病发病率的增加、CVD 诊断研发支出的增加以及成熟的技术医疗保健基础设施。 2022 年,美国占据该地区最大的市场份额。

根据 2022 年心脏病和中风统计情况说明书,每 40 秒就有一个人在美国预计将出现心肌梗塞。同样,疾病预防控制中心 2021 年 9 月的报告指出,该国 40 岁及以上的人口约有 650 万人患有外周动脉疾病。据美国心脏协会称,美国每 34 秒就有一人死于 CVD。 2020 年,该国近 697,000 人死于心脏病,即五分之一的死亡人数。此外,根据加拿大心脏和中风基金会 2022 年 2 月的报告,加拿大约有 75 万人患有心力衰竭,每年有 10 万人被诊断患有心力衰竭。同样,根据国家卫生统计中心的数据,2023 年 2 月,2021 年美国约有 695,000 人死于心脏病。该国每年约有 150 万人发生心脏病和中风。

美国心血管疾病发病率的上升归因于高血压、高胆固醇水平、低高密度脂蛋白胆固醇、肥胖、糖尿病、腹部肥胖和吸烟等危险因素的患病率不断上升。心脏病每年给美国造成约 2190 亿美元的损失。这一总成本包括医疗保健服务、药物和过早死亡的成本。

此外,该地区越来越多的市场参与者引入创新和技术先进的心脏标记物的战略测试和设备预计将有助于市场的增长。 2021 年 7 月,贝克曼库尔特与 Quidel Corporation 达成最终协议,获得与用于治疗充血性心力衰竭的贝克曼库尔特分析仪的 BNP 检测相关的制造、分销和销售的所有权利。因此,上述因素预计将有助于该地区市场的增长。

行业发展和未来机遇:

全球心脏标记物市场主要参与者采取的各种举措如下:

  1. 2021 年 7 月,Beckman Coulter 与 Quidel Corporation 达成最终协议,获得与 Beckman Coulter 分析仪 BNP 检测的制造、分销和销售相关的所有权利。根据协议条款,Quidel 继续向贝克曼库尔特生产和供应与检测相关的某些组件。 Beckman Coulter 以 Access BNP 品牌独家生产并向客户销售 BNP 检测。
  2. 2021 年 4 月,F. Hoffmann-La Roche 推出了一系列针对其关键心脏生物标志物的五种新应用(cTnT-hs) 与其 Elecsys 技术相结合。这些生物标志物已被证明可以成功地控制心血管疾病,并可以帮助临床医生诊断心脏病和治疗患者的心力衰竭。这改进了风险识别和诊断,并使公司能够从现有产品中获得更大的收入。

竞争格局和主要公司:< /strong>

心脏生物标志物市场的一些知名参与者包括 Abbott Diagnostics、Roche Diagnostics、bioMérieux SA、Thermo Fisher Scientific Inc.、Beckman Coulter, Inc. .(丹纳赫); Bio-Rad 实验室;三一生物科技有限公司;创造性诊断;迪亚酶实验室公司;西门子公司和 Quidel 公司。这些公司专注于推出新的高科技产品、现有产品的进步以及地域扩张,以满足全球不断增长的消费者需求。心脏生物标志物市场公司强调各种增长战略,例如合作、产品发布、业务扩张和协议等,以保持其在全球市场的地位并增加其专业产品组合的产品范围。他们在全球范围内拥有广泛的业务,这使他们能够为大量客户提供服务,从而增加他们的心脏标记物市场份额。

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

  • Abbott Diagnostics
  • Roche Diagnostics
  • bioMérieux SA
  • Thermo Fisher Scientific Inc.
  • Beckman Coulter, Inc. (Danaher)
  • Bio-Rad Laboratories
  • Trinity Biotech Plc
  • Creative Diagnostics
  • Diazyme Laboratories, Inc
  • Siemens AG
  • Quidel Corporation

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports